Skip to main content

Advertisement

Table 5 Efficacy outcomes from the double-blind period

From: Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies

   Paliperidone p Value
Efficacy measure PP ER (paliperidone ER vs PP)
PANSS total score n = 191 n = 104  
Double-blind baseline mean (SD) 50.8 (10.9) 51.0 (11.4)  
LS mean (SE) change from baseline to end point 2.5 (0.9) 6.0 (1.3) 0.025
PSP score n = 188 n = 103  
Double-blind baseline mean (SD) 72.7 (10.5) 70.8 (10.9)  
LS mean (SE) change from baseline to end point −1.4 (0.8) −3.3 (1.1) 0.156
CGI-S score n = 191 n = 104  
Double-blind baseline mean (SD) 2.6 (0.8) 2.6 (0.8)  
LS mean (SE) change from baseline to end point 0.2 (0.1) 0.3 (0.1) 0.095
  1. CGI-S Clinical Global Impressions–Severity, ER extended release, LS least squares, PANSS Positive and Negative Syndrome Scale, PP paliperidone palmitate, PSP Personal and Social Performance, SD standard deviation, SE standard error.